insights_auto
Why is CTSO up 4.35%?
Dive Deeperchevron_right
CTSO:NASDAQ
Cytosorbents Corp
$4.80
arrow_upward
+4.35%(+0.20) 1D
Nov 6, 4:00:00 PM GMT-5 · USD
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for CTSO...
Open
$4.56
High
$5.32
Low
$4.52
Mkt. cap
15.13M
Avg. vol.
53.19K
Volume
13.97K
52-wk high
$17.00
52-wk low
$2.84
EPS
-$5.80
Beta
1.49
Shares outstanding
3.15M
No. of employees
129
Open
$4.56
High
$5.32
Low
$4.52
Mkt. cap
15.13M
Avg. vol.
53.19K
Volume
13.97K
52-wk high
$17.00
52-wk low
$2.84
EPS
-$5.80
Beta
1.49
Shares outstanding
3.15M
No. of employees
129
News stories
From web sources and news partners
The Globe and Mail
·
18 minutes ago
Here's Why I'm Still Investing in the S&P 500, Even if a Bear Market Is Coming
Jamaica Gleaner
·
1 hour ago
AI stocks halt their brutal, worldwide sell-off as Wall Street trims its loss for the week
Yahoo Finance
·
23 hours ago
Tech stocks are now cheaper than the S&P 500 for the first time since 2017 — here's what history says comes next: Chart of the Day
Bloomberg
·
22 hours ago
Wall Street Strategists Call Stock Rout a Fresh Reason to Buy
Profile
CytoSorbents Corporation is a publicly traded company located in Princeton, New Jersey.
CytoSorbents sells a cytokine adsorbing column — a blood purification technology based on porous polymer beads that act like sponges in an attempt to remove harmful inflammatory mediators like Cytokines, Bilirubin, Myoglobin from the blood.
The use of hemoperfusion columns is generally limited to patients who are critically ill in high-resource counties, and they require a patient to be connected to a hemofiltration system such as Dialysis, Hemofiltration Cardiopulmonary bypass or ECMO. Other blood purification devices are using different technologies with different performance parameters. This is including polymyxin B hemoperfusion columns, which failed to show significance in a clinical trial for sepsis. The CytoSorb technology has actually the largest body of clinical data confirming safety and efficacy. Clinicaltrials.gov is giving an overview over running research projects.
CytoSorbents was awarded a $3.8 million contract by Defense Advanced Research Projects Agency for its “Dialysis-Like Therapeutics” program to treat sepsis by removing cytokines and pathogen-derived toxins. Wikipedia
About Cytosorbents Corp
CEO-
Employees129
Founded1997
Headquarters-
SectorHealth Care
IndustryMedical device
Websitecytosorbents.com